Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin |
| |
Authors: | Trifiletti A Lasco A Scamardi R Pizzoleo M A Gaudio A La Rocca R Morini E Frisina N |
| |
Affiliation: | Department of Internal Medicine, University of Messina, Messina, Italy. Aldo.Trifiletti@unime.it |
| |
Abstract: | This study assessed hemostatic effects of an HMC-CoA reductase inhibitor, atorvastatin, on different parameters in 32 hypercholesterolemic patients of both sexes. In the patients and in 25 control subjects, plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor (PAI-1), D-dimer, prothrombin fragment 1 + 2 (F1 + 2), total cholesterol, triglycerides and fibrinogen had been measured. All these parameters were evaluated in patients after 6 and 12 months of treatment with atorvastatin at a dosage of 20 mg/day. This treatment significantly lowered the total cholesterol level in all patients. Moreover, after 6 months of atorvastatin treatment, PAI-1 and F1 + 2, which were both increased at baseline, were significantly reduced. This reduction continued after 12 months. The present results show that a reduction of hemostatic abnormalities, which exist in hypercholesterolemia, may be another important effect of the atorvastatin therapy. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|